Could a 7-Day pill blast beat a 14-Day regimen for stomach bug?

NCT ID NCT07352098

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a 7-day high-dose vonoprazan-amoxicillin treatment to a standard 14-day regimen for eradicating H. pylori, a common stomach bacteria linked to ulcers and cancer. About 290 adults with confirmed infection will be randomly assigned to one of the two groups. The goal is to see if the shorter course works just as well with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

vonoprazan and amoxicillin

What this could lead to

If successful, this could offer a shorter, more convenient treatment for H. pylori infection, potentially improving patient adherence and reducing side effects.

What could go wrong

This is an early-stage trial with only 290 participants, so results may not apply to everyone. The higher dose could also increase the risk of side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kashi Prefecture Hospital of Traditional Chinese Medicine

    Kashgar, Xinjiang, 844000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••